Key Takeaways RDY posted Q2 earnings of 19 cents per ADS and $992M in sales; beats estimates on both counts.Global Generics revenues climbed 10%, fueled by new launches and Europe portfolio gains.The CHMP issued a positive opinion for RDY/ALVO's AVT03, a biosimilar to Amgen's Prolia and Xgeva.Dr. Reddy's Laboratories Limited (RDY) reported second-quarter fiscal 2026 earnings of 19 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 18 cents. The company reported earnings of ...